|
|
 |
Register for updates, request contact from a sales rep or MSL, or request medical, reimbursement, or clinical trials information.
|
|
|
|
Get reimbursement support and assistance with CORE: Cephalon Oncology Reimbursement Expertise.
|
|
|
|
Submit your own study proposal to become an investigator with Cephalon Oncology.
|
|
|
|
|
|
The Cephalon Oncology drug discovery program is delivering novel, cytotoxic, and molecular-targeted agents to treat numerous cancers.
Molecular-targeted agents
CEP-701 (lestaurtinib) FLT-3, TrkA, and JAK2/STAT protein tyrosine kinase inhibitor
In development for treatment of:
- Acute myelogenous leukemia
- Myeloproliferative disorders
CEP-11981 TIE-2/pan VEGFR kinase inhibitor
In development for treatment of:
- Multiple solid and hematological tumors
CEP-18770 proteasome inhibitor
In development for treatment of:
- Multiple myeloma
- Lymphoma
- Solid tumors
CEP-9722 PARP (poly (ADP-ribose) polymerase) inhibitor
In development for treatment of:
- Breast and ovarian tumors
- Radio- and chemo-sensitizer for resistant cancers
Cytotoxic agent
Bendamustine HCl
In development for treatment of:
- Non-Hodgkin’s lymphoma
- Chronic lymphocytic leukemia
- Multiple myeloma
- Small cell lung cancer
Novel agents
Anaplastic lymphoma kinase (ALK) receptor tyrosine kinase (RTK) inhibitors
In development for treatment of:
- Anaplastic large-cell lymphoma (ALCL)
- Inflammatory myofibroblastic tumors (IMT)
- Glioblastoma
cMET receptor tyrosine kinase (RTK) inhibitors
In development for treatment of:
- Multiple myeloma
- Multiple solid and hematologic cancers
- Papillary renal carcinoma
- Gastric cancer
- Osteo- and soft-tissue sarcomas
|
|
|